<DOC>
	<DOCNO>NCT00274443</DOCNO>
	<brief_summary>This open-label dose escalation trial use ABI-007 plus carboplatin .</brief_summary>
	<brief_title>An Open Label Study Patients With Advanced NSCLC With ABI-007 ( Abraxane ) Combination With Carboplatin</brief_title>
	<detailed_description>This multicenter study conduct study site Russia Ukraine various dos ABI-007 ( Abraxane ) give combination carboplatin patient non-small cell lung cancer determine recommend dose schedule combination therapy Phase III trial . The primary objective study obtain preliminary information antitumor activity adverse event ABI-007 combination carboplatin .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Histologically cytologically confirm NSCLC Stage IIIB pleural effusion evidence inoperable local recurrence metastasis ( Stage IV ) . Male nonpregnant nonlactating female , ≥ 18 year age . ( ) If female patient childbearing potential , evidence regular menstrual period , must negative serum pregnancy test ( βhCG ) document within 72 hour first administration study drug . ( ) If sexually active , patient must agree utilize contraception consider adequate appropriate investigator . No current active malignancy . Measurable disease Patients must receive prior therapy treatment metastatic disease . Patient follow blood count baseline : ( ) ANC ≥ 1.5 x 109/L ; ( ) platelets ≥ 100 x 109/L ; ( ) Hgb ≥ 9 g/dL . Patient follow blood chemistry level baseline : ( ) AST ( SGOT ) , ALT ( SGPT ) ≤ 1.5x upper limit normal range ( ULN ) ; ( ) total bilirubin NORMAL ; ( ) creatinine ≤ 1.5 mg/dL . Expected survival &gt; 12 week . ECOG performance status 0 1 . Patient his/her legally authorize representative guardian inform nature study , agree participate study , sign Informed Consent form prior participation studyrelated activity . Evidence active brain metastasis , include leptomeningeal involvement . Prior evidence brain metastasis permit treated stable therapy least 1 month . The evidence metastasis bone metastases nonmeasurable disease . Patient preexist peripheral neuropathy grade 2 , 3 , 4 . Patient receive radiotherapy last 4 week , except nontarget lesion . Prior radiation target lesion permit clear progression lesion since radiation complete . Patient clinically significant concurrent illness . Patient , investigator 's opinion , unlikely able complete study End Study visit . Patient receive treatment cytotoxic chemotherapeutic agent investigational drug within previous 4 week ; Patient history allergy hypersensitivity study drug . Patient serious medical risk factor involve major organ system investigator considers unsafe patient receive experimental research drug . Patient enrol clinical protocol investigational trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>